These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29485852)

  • 1. Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment.
    Weïwer M; Xu Q; Gale JP; Lewis M; Campbell AJ; Schroeder FA; Van de Bittner GC; Walk M; Amaya A; Su P; D Ordevic L; Sacher JR; Skepner A; Fei D; Dennehy K; Nguyen S; Faloon PW; Perez J; Cottrell JR; Liu F; Palmer M; Pan JQ; Hooker JM; Zhang YL; Scolnick E; Wagner FF; Holson EB
    ACS Chem Biol; 2018 Apr; 13(4):1038-1047. PubMed ID: 29485852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.
    Masri B; Salahpour A; Didriksen M; Ghisi V; Beaulieu JM; Gainetdinov RR; Caron MG
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13656-61. PubMed ID: 18768802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β-Arrestin to Dopamine-Dependent Functions.
    Rose SJ; Pack TF; Peterson SM; Payne K; Borrelli E; Caron MG
    Neuropsychopharmacology; 2018 Apr; 43(5):1164-1173. PubMed ID: 29068002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor.
    Peterson SM; Pack TF; Wilkins AD; Urs NM; Urban DJ; Bass CE; Lichtarge O; Caron MG
    Proc Natl Acad Sci U S A; 2015 Jun; 112(22):7097-102. PubMed ID: 25964346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-Like Efficacy of Dopamine D
    Sahlholm K; Gómez-Soler M; Valle-León M; López-Cano M; Taura JJ; Ciruela F; Fernández-Dueñas V
    Mol Neurobiol; 2018 Jun; 55(6):4952-4958. PubMed ID: 28779351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.
    Allen JA; Yost JM; Setola V; Chen X; Sassano MF; Chen M; Peterson S; Yadav PN; Huang XP; Feng B; Jensen NH; Che X; Bai X; Frye SV; Wetsel WC; Caron MG; Javitch JA; Roth BL; Jin J
    Proc Natl Acad Sci U S A; 2011 Nov; 108(45):18488-93. PubMed ID: 22025698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties.
    Urs NM; Gee SM; Pack TF; McCorvy JD; Evron T; Snyder JC; Yang X; Rodriguiz RM; Borrelli E; Wetsel WC; Jin J; Roth BL; O'Donnell P; Caron MG
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):E8178-E8186. PubMed ID: 27911814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Concepts in Dopamine D
    Urs NM; Peterson SM; Caron MG
    Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice.
    Park SM; Chen M; Schmerberg CM; Dulman RS; Rodriguiz RM; Caron MG; Jin J; Wetsel WC
    Neuropsychopharmacology; 2016 Feb; 41(3):704-15. PubMed ID: 26129680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.
    Deslauriers J; Desmarais C; Sarret P; Grignon S
    J Mol Neurosci; 2013 May; 50(1):134-45. PubMed ID: 22975849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor, Ligand and Transducer Contributions to Dopamine D2 Receptor Functional Selectivity.
    Peterson SM; Pack TF; Caron MG
    PLoS One; 2015; 10(10):e0141637. PubMed ID: 26516769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Functional Selectivity Relationship Studies on A-86929 Analogs and Small Aryl Fragments toward the Discovery of Biased Dopamine D1 Receptor Agonists.
    Li H; Mirabel R; Zimmerman J; Ghiviriga I; Phidd DK; Horenstein N; Urs NM
    ACS Chem Neurosci; 2022 Jun; 13(12):1818-1831. PubMed ID: 35658399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases.
    Liu H; Ma H; Zeng X; Wu C; Acharya S; Sudan SK; Zhang X
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGS2 modulates the activity and internalization of dopamine D2 receptors in neuroblastoma N2A cells.
    Luessen DJ; Hinshaw TP; Sun H; Howlett AC; Marrs G; McCool BA; Chen R
    Neuropharmacology; 2016 Nov; 110(Pt A):297-307. PubMed ID: 27528587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics simulation of biased agonists at the dopamine D2 receptor suggests the mechanism of receptor functional selectivity.
    Montgomery D; Campbell A; Sullivan HJ; Wu C
    J Biomol Struct Dyn; 2019 Aug; 37(12):3206-3225. PubMed ID: 30124143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.
    Urs NM; Snyder JC; Jacobsen JP; Peterson SM; Caron MG
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20732-7. PubMed ID: 23188793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects.
    Su P; Li S; Chen S; Lipina TV; Wang M; Lai TK; Lee FH; Zhang H; Zhai D; Ferguson SS; Nobrega JN; Wong AH; Roder JC; Fletcher PJ; Liu F
    Neuron; 2014 Dec; 84(6):1302-16. PubMed ID: 25433637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.
    de Bartolomeis A; Ciccarelli M; De Simone G; Mazza B; Barone A; Vellucci L
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative Bioluminescence Resonance Energy Transfer Assay Reveals Differential Agonist-Induced D2 Receptor Intracellular Trafficking and Arrestin-3 Recruitment.
    De Vries L; Finana F; Cathala C; Ronsin B; Cussac D
    Mol Pharmacol; 2019 Sep; 96(3):308-319. PubMed ID: 31266815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.
    Brust TF; Hayes MP; Roman DL; Burris KD; Watts VJ
    J Pharmacol Exp Ther; 2015 Mar; 352(3):480-93. PubMed ID: 25539635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.